[{'publishedAt': '2024-08-20T21:46:38Z',
  'author': 'New York Times',
  'urlToImage': 'https://dnyuz.com/wp-content/uploads/2024/08/He-Regulated-Medical-Devices-His-Wife-Represented-Their-Makers.jpg',
  'description': 'He Regulated Medical Devices. His Wife Represented Their Makers...\r\n\n \n \n \n (Second column, 4th story, link)\r\n\n \r\n\n \r\n\n \n \n Drudge Report Feed needs your support!\xa0\xa0 Become a Patron',
  'source': {'name': 'Dnyuz.com', 'id': None},
  'title': 'He Regulated Medical Devices. His Wife Represented Their Makers...',
  'url': 'https://dnyuz.com/2024/08/20/he-regulated-medical-devices-his-wife-represented-their-makers/',
  'content': 'For 15 years, Dr. Jeffrey E. Shuren was the federal official charged with ensuring the safety of a vast array of medical devices including artificial knees, breast implants and Covid tests.\r\nWhen he … [+21148 chars]'},
 {'publishedAt': '2024-09-03T21:24:05Z',
  'author': 'Investing.com',
  'urlToImage': 'https://i-invdn-com.investing.com/redesign/images/seo/investing_300X300.png',
  'description': 'Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement',
  'source': {'name': 'Investing.com', 'id': None},
  'title': 'Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement',
  'url': 'https://www.investing.com/news/press-releases/royalty-pharma-and-ascendis-pharma-enter-into-150-million-royalty-funding-agreement-93CH-3599313',
  'content': 'NEW YORK and COPENHAGEN, Denmark, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Ascendis Pharma A/S (Nasdaq: NASDAQ:ASND) today announced that Royalty Pharma and Ascendis P… [+10598 chars]'},
 {'publishedAt': '2024-09-03T21:14:00Z',
  'author': 'Royalty Pharma plc',
  'urlToImage': 'https://ml.globenewswire.com/Resource/Download/d605b3b0-7ba0-46e1-a2d4-439ca98694f8',
  'description': 'Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the Yorvipath U.S. commercial launch, and general corporate purposes Proceeds to support continued development and commercialization of Endocrine Rar…',
  'source': {'name': 'GlobeNewswire', 'id': None},
  'title': 'Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement',
  'url': 'https://www.globenewswire.com/news-release/2024/09/03/2940138/0/en/Royalty-Pharma-and-Ascendis-Pharma-Enter-Into-150-Million-Royalty-Funding-Agreement.html',
  'content': 'NEW YORK and COPENHAGEN, Denmark, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Ascendis Pharma A/S (Nasdaq: ASND) today announced that Royalty Pharma and Ascendis Pharma B… [+10428 chars]'},
 {'publishedAt': '2024-09-03T21:06:00Z',
  'author': 'Ascendis Pharma',
  'urlToImage': 'https://ml.globenewswire.com/Resource/Download/b4b7c29a-478e-4a8e-b23b-b6a1cb18aee8',
  'description': 'Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the YORVIPATH® U.S. commercial launch, and general corporate purposes Proceeds to support continued development and commercialization of Endocrine Ra…',
  'source': {'name': 'GlobeNewswire', 'id': None},
  'title': 'Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement',
  'url': 'https://www.globenewswire.com/news-release/2024/09/03/2940137/0/en/Ascendis-Pharma-and-Royalty-Pharma-Enter-into-150-Million-Royalty-Funding-Agreement.html',
  'content': 'COPENHAGEN, Denmark and NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) and Royalty Pharma plc (Nasdaq: RPRX) today announced that Ascendis Pharma Bone Diseases A/S, a… [+10039 chars]'}]